Trial Profile

Study of NT219 in combination with gemcitabine for the treatment of advanced pancreatic cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; NT 219 (Primary)
Indications Pancreatic cancer
Focus Adverse reactions; First in man
Sponsors Purple Biotech

Most Recent Events

01 Nov 2017 According to a Kitov Pharmaceuticals media release, an IND submission is expected in the first half of 2019.
16 Aug 2017 According to a Kitov Pharmaceuticals media release, the company expects to initiate the clinical trial in 2018.
17 Jan 2017 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com